{
    "Trade/Device Name(s)": [
        "QUANTA Flash\u2122 DGP IgA",
        "QUANTA Flash\u2122 DGP IgG",
        "QUANTA Flash\u2122 DGP IgA Calibrators",
        "QUANTA Flash\u2122 DGP IgG Calibrators",
        "QUANTA Flash\u2122 DGP IgA Controls",
        "QUANTA Flash\u2122 DGP IgG Controls"
    ],
    "Submitter Information": "INOVA Diagnostics, Inc",
    "510(k) Number": "K113863",
    "Predicate Device Reference 510(k) Number(s)": [
        "K052143",
        "K052142"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MST",
        "JIX",
        "JJX"
    ],
    "Summary Letter Date": "October 23, 2012",
    "Summary Letter Received Date": "September 20, 2012",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.5750",
        "21 CFR 862.1150"
    ],
    "Regulation Name(s)": [
        "Radioallergosorbent (RAST) Immunological Test System",
        "Calibrator, secondary"
    ],
    "Analyte Class(es)": [
        "immunology",
        "autoimmune"
    ],
    "Analyte(s)": [
        "IgA antibodies to synthetic, deamidated gliadin peptides",
        "IgG antibodies to synthetic, deamidated gliadin peptides",
        "DGP IgA antibodies",
        "DGP IgG antibodies"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [
        ""
    ],
    "Instrument(s)/Platform(s)": [
        "BIO-FLASH Instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CIA)"
    ],
    "Methodologies": [
        "Solid phase immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for QUANTA Flash DGP IgA/IgG assays, calibrators, and controls for semi-quantitative detection of IgA/IgG antibodies to deamidated gliadin peptides in human serum using chemiluminescent immunoassay on BIO-FLASH",
    "Indications for Use Summary": "QUANTA Flash DGP IgA/IgG assays are chemiluminescent immunoassays for the semi-quantitative determination of IgA and IgG antibodies to synthetic, deamidated gliadin peptides in human serum; aids in the diagnosis of celiac disease and dermatitis herpetiformis (IgA assay), and celiac disease in both IgA sufficient and deficient subjects (IgG assay), used in conjunction with clinical findings and other laboratory tests.",
    "fda_folder": "Immunology"
}